As we know, a commonly used chemotherapeutic agent, Cisplatin, is very effective in treating malignant tumors. Often, however, patients experience irreversible hearing loss and/or tinnitus. The percentage of patients suffering from Cisplatin ototoxicity is between 11 percent and 97 percent with an average incidence of 62 percent of adult patients, and 60 percent of pediatric patients being affected overall (Chirtes and Albu, 2014).
A decrease in ototoxicity of these lifesaving drugs is a major area of investigation in oncology, otolaryngology, and hearing research. Several potential otoprotective agents have been investigated but none have received full approval by the U.S. Federal Drug Administration. Febles et al (2022) studied the effects of an otoprotective treatment that was comprised of an antioxidant, a p53 inhibitor, and a neurotrophic.
In-vitro and ex vivo findings in rats demonstrated that with the three agents in combination as an otoprotective, Cisplatin-induced hair cell damage, death, and spiral ganglion fiber loss were significantly reduced.
The authors conclude and recommend an immediate local administration of the cocktail may promise clinical prevention of Cisplatin-induced sensorineural hearing loss and tinnitus.
References
Chirtes F, Albu S. (2014) Prevention and restoration of hearing loss associated with use of Cisplatin. Biomed Res Int (925485):1–9.
Febles NK, Bauer MA, Ding B, Zhu X ,Gallant ND, Frisina RD. (2022). A combinatorial approach to protect sensory tissue against cisplatin-induced ototoxicity. Hear Res (415) 108430:1–11.
Recent Posts
Mississippi and Missouri Go Live in ASLP Compact
The Audiology & Speech-Language Pathology Interstate Compact (ASLP-IC) continues to expand, with Mississippi officially going live on November 9, and Missouri following on November 16. With…
Senators Merkley and Gillibrand Introduce Professional Student Degree Act
Senators Jeff Merkley (D-OR) and Kirsten Gillibrand (D-NY) have introduced the Professional Student Degree Act in the Senate, companion legislation to H.R. 6718, introduced in the…
CMS Offers States an Optional Pause on Medicaid Work Requirement Enforcement
On November 13, 2026, CMS announced that states may protect otherwise eligible Medicaid applicants and beneficiaries from work-requirement-related coverage denials through June 30, 2027. The…



